摘要
目的观察糖皮质激素(GC)联合长效β2-受体激动剂(LABA)对糖皮质激素抵抗型(SR)哮喘患者哮喘症状和肺功能的影响,探讨GC联合LABA对SR哮喘有无治疗作用。方法SR哮喘患者20例,随机分为A、B,每组各10例。A组吸入沙美特罗50ug,2次/天和氟替卡松500ug,2次/天。B组每天吸入氟替卡松500ug,2次/天,急性发作时吸入沙丁胺醇,疗程4周,疗程开始及结束时评价哮喘临床积分和肺功能检查。结果治疗后A组患者哮喘临床积分显著降低(与A组治疗前比较P<0.01;与B组治疗后比较P<0.05),肺功能指标用力肺活量(FVC%)。第1秒用力呼吸容积(FEV1%)最大呼气流量(PEF%),50%肺活量时最大呼气流量(V50%),25%肺活量时最大呼气流量(V25%),均显著增高。B组治疗后与治疗前比较,上述各项指标均无显著改变(P>0.05)。结论CS联合LABA是治疗SR哮喘的有效方法。
Objective To investigate the effect of glucocorticoid and long acting β_2 agonistics on the treatment of steroid-resistant asthma,the impact on symptoms and lung function.Of patients with steroid-resistant asthma was evaluated.Methods Twenty patients with steroid-resistant asthma had been assigned to group A or B,10 patients per group.patients in group A received salmeterol(50ug a time,two times a day,for 4 weeks) and FP (500ug a time,two times a day,for 4 weeks).patients in group B received FP(500ug a time,two times a day,for 4 weeks),and inhaled salbutamol on acute occasions.Asthmatic symptoms score and lung function were measured at the begining and at the end of the study.Results In group A,indices of lung function FVC%,FEV_1%,PEF%,V50%,V25%,increased significantly,meanwhile,asthmatic symptoms scored decreased significantly(P<0.01,comparing with group B,no significant change in all the indices had been observed after the treatment.Conclusion Glucocorticoid and long acting β_2 agonistics may serve as an effective option for the treatment of steroid-resistant asthma.
出处
《临床肺科杂志》
2005年第5期626-627,共2页
Journal of Clinical Pulmonary Medicine
